Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Valproate linked with autism risk

Pregnant women taking valproate may increase their child’s risk of developing autism, early data from a study published in Neurology suggest (2008;71:1923).

The ongoing study found that out of 64 children exposed to valproate, four (6.3 per cent) had autism or features of the disorder, making the children whose mothers had taken the drug during pregnancy seven times more likely than the control group to develop autism (incidence: 0.9 per cent). This was also higher than the reported incidence of six per 1,000 children in the general population.

The study, conducted by the Liverpool and Manchester Neurodevelopment Group, recruited 632 children between 2000 and 2006, nearly half of whom were exposed to epilepsy drugs during gestation.

Sixty four children were exposed to valproate, 44 to lamotrigine, 76 to carbamazepine and 65 to other epilepsy drugs. Nine children have been diagnosed with autism and one has shown symptoms of the disorder. Seven of these had mothers who took an epilepsy drug while pregnant.

The study’s author Gus Baker emphasised that more research needs to be done and said: “This is a relatively young cohort with many children falling below the average age of detection and diagnosis of ASD [autistic spectrum disorders].”

He added: “However, women who take valproate while pregnant should be informed of the possible risks of autism and are encouraged to discuss them with their doctor.”

Commenting on the study, a spokeswoman for Sanofi-Aventis, which markets Epilim, said: “Valproate has been used for many years and epilepsy is a complex disorder. The management of it is complex, particularly during pregnancy when seizure control is critical.”

She added that all epilepsy drugs have been associated with some degree of genetic malformation in children but that seizures themselves can also lead to this and can be fatal.

“It is critical women receive pre- conception counselling from pharmacists to find out what the most appropriate treatment is for them,” she told The Journal.

Citation: The Pharmaceutical Journal URI: 10041190

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.